drugset
drugset / Trial / NCT00005633

Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma

NCT00005633 ↗

Phase 1 Completed Memorial Sloan Kettering Cancer Center National Cancer Institute (NCI) · collab
Treatment

Summary

RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of vaccine therapy in treating patients with stage III or stage IV melanoma.

Timeline

Start
1999-06
Primary completion
2002-06
Completion
2002-06

Drugs

EvaluationDrugModalityDoseRoute
Subject gp209-2M antigen Peptide — Subcutaneous
Subject tyrosinase peptide Peptide — Subcutaneous
Background OVA BiP peptide Peptide — Subcutaneous
Background recombinant 70-kD heat-shock protein Protein / enzyme biologic — Subcutaneous

Indications

cutaneous melanoma